Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.
Matthew J. Wieduwilt(Atrium Health Wake Forest Baptist), Richard M. Stone(Dana-Farber Cancer Institute), James K. Mangan(UC San Diego Health System), Alice S. Mims(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Kenneth Byrd(University of Kansas Medical Center), Kimberley Doucette(Georgetown University), Harry P. Erba(Michigan Center for Translational Pathology), Shira Dinner(Dana-Farber Cancer Institute), Gregory A. Masters(Christiana Care Health System), Mark R. Litzow(Mayo Clinic in Arizona), Rebecca Teske(Alliance Data (United States)), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Jun Yin(Mayo Clinic), Ali W. Bseiso(University Hospitals of Cleveland), Wendy Stock(University of Chicago), Katarzyna Jamieson(University of North Carolina at Chapel Hill), Oudom Kour(Alliance Data (United States))
Cited by 49
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k